Research programme: erythropoietin/albumin - Teva
Alternative Names: Albumin/erythropoietin; Albupoietin; EPO/albumin; Long-acting EPO - Teva; Long-acting erythropoietinLatest Information Update: 02 Oct 2021
At a glance
- Originator CoGenesys
- Developer Teva Pharmaceutical Industries
- Class Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 22 Feb 2008 CoGenesys has been acquired and merged into Teva Pharmaceutical Industries
- 30 Aug 2006 This programme is available for licensing (http://www.cogenesys.com)
- 12 Jun 2006 CoGenesys has acquired this programme from Human Genome Sciences